C4 Therapeutics (CCCC) Assets Average (2020 - 2026)

C4 Therapeutics has reported Assets Average for 7 years, with the latest figure at $344.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 2.81% year-over-year to $344.0 million; the trailing twelve-month figure through Mar 2026 stood at $344.0 million (up 2.81% YoY), and the FY2025 full-year result was $354.3 million, down 2.39% from the prior year.
• Assets Average for Q1 2026 stood at $344.0 million, up from $312.3 million in the prior quarter.
• The five-year high for Assets Average was $511.1 million in Q1 2022, with the low at $281.0 million in Q3 2025.
• Average Assets Average over 5 years is $385.0 million, with a median of $378.6 million recorded in 2024.
• Year-over-year, Assets Average surged 32.05% in 2022 and retreated 25.78% in 2023.
• Tracing CCCC's Assets Average over 5 years: stood at $446.1 million in 2022, then fell by 20.49% to $354.7 million in 2023, then rose by 2.28% to $362.8 million in 2024, then slipped by 13.93% to $312.3 million in 2025, then gained by 10.15% to $344.0 million in 2026.
• The last three Assets Average figures came in at $344.0 million (Q1 2026), $312.3 million (Q4 2025), and $281.0 million (Q3 2025), per Business Quant data.

Peer Comparison